Statement: Patients with dementia or schizophrenia may be eligible for the primary trial and the secondary trial.
Primary_evidence: Inclusion Criteria:   Patients   with unilateral primary cancer pathologically confirmed before neoadjuvant chemotherapy (NAC)   who received NAC   with detectable lesion / clip marker on ultrasound   with cT1-T3 tumors   clinical and imaging complete or near-complete response on MRI   with informed consent Exclusion Criteria:   Multifocal cancer   Residual microcalcification   Contralateral breast cancer
Secondary_evidence: Inclusion Criteria:(main conditions)   Female patients 18 to 75 years of age with metastatic breast cancer histologically/cytologically confirmed not amenable to curative surgery or radiotherapy and who have received at least two prior chemotherapy regimens including anthracyclines,taxanes,antimetabolite and vinca-alkaloid and are no longer candidate for these drugs,   Karnofsky performance score of at least 70 %, adequate haematological, hepatic and renal functions and ECG without clinically relevant abnormality. Exclusion Criteria:   Concurrent serious uncontrolled medical disorder,   known or clinical evidence of brain metastases or leptomeningeal involvement,   pulmonary lymphangitis or symptomatic pleural effusion or symptomatic ascites,   history of second primary malignancy,   HIV infection, preexisting neuropathy,   pregnancy or breast feeding.